This Cancer Drug Is So Effective, The FDA Approved It Immediately
June 11, 2017
A new cancer drug has overwhelmingly helped shrink or eradicate tumors in patients whose cancer had resisted every other form of treatment.
The results, published in the journal Science, are so striking that the Food and Drug Administration already has approved the drug.

Image credit: Merck
The study followed 86 cancer patients with tumors of the pancreas, prostate, uterus or bone. Each patient was given pembrolizumab, which also goes by the brand name Keytruda.
After taking the drug, 66 patients had their tumors shrink substantially and stabilize, instead of continuing to grow. Among them were 18 patients whose tumors vanished and have not returned.
According to the New York Times, this is the first time a drug has been approved for use against tumors that share a particular genetic profile, regardless of where they appear in the body.
Dr. Jack Jacoub, a medical oncologist and director of thoracic oncology at Memorial Care Cancer Institute at Orange Coast Memorial Medical Center, said "The FDA doesn't take these kinds of things lightly. The data was so good, they had to approve it."
Click Here For The Most Popular On Sunny Skyz
Football Player Asks Friend With Down Syndrome To Homecoming
This Pit Bull Was Days Away From Being Euthanized. Now, He's A Police Hero
Hospital Staff Go Above And Beyond To Keep Couple’s 62-Year Anniversary Tradition Alive
Man Digging A Duck Pond Uncovers Mysterious Underground Tunnel Made Of Seashells
Hope And Hard Work: Jail Resident Makes History In Clarke County
Strangers Send Man Birthday Wishes At The Exact Minute His Late Mom Used To
They Found Out He Couldn’t Afford The Shirt. Their Response Went Viral For All The Right Reasons
Mom And Daughter Rock Out In The Car - The Baby’s Reaction Is Priceless!
The Last Runner To Cross The NYC Marathon Finish Line Got The Biggest Ovation Of All
Dad’s Smelly Socks Help Reunite 93-Year-Old With His Missing Dog
He Drove Past A Giant Pile Of Leaves, Then Noticed Eyes Staring Back
